Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

APELLIS PHARMACEUTICALS, INC.

(APLS)
  Report
Delayed Nasdaq  -  04:00 2022-09-30 pm EDT
68.30 USD   +4.42%
09/30Aao 2022 : Treatment of Geographic Atrophy Secondary to AMD with Pegcetacoplan: Two-Year Outcomes from the Randomized Phase 3 OAKS and DERBY Trials
PU
09/30Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacoplan Led to Preservation of Function in High-Risk Areas of the Retina in Patients with Geographic Atrophy (GA) at AAO Annual Meeting
GL
09/30Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacoplan Led to Preservation of Function in High-Risk Areas of the Retina in Patients with Geographic Atrophy (GA) at AAO Annual Meeting
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Apellis Pharmaceuticals Narrows Q2 Loss, Revenue Rises

08/08/2022 | 04:58pm EDT


© MT Newswires 2022
All news about APELLIS PHARMACEUTICALS, INC.
09/30Aao 2022 : Treatment of Geographic Atrophy Secondary to AMD with Pegcetacoplan: Two-Year O..
PU
09/30Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacopla..
GL
09/30Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacopla..
GL
09/30Apellis Pharmaceuticals, Inc. Announces 24-Month Phase 3 Post Hoc Results Showing Treat..
CI
09/30Apellis Announces Four Oral Presentations of Data from the Phase 3 DERBY and OAKS Studi..
GL
09/30Apellis Announces Four Oral Presentations of Data from the Phase 3 DERBY and OAKS Studi..
GL
09/16Transcript : Apellis Pharmaceuticals, Inc. Presents at BofA Securities Global..
CI
09/12Insider Sell: Apellis Pharmaceuticals
MT
09/12Apellis Pharmaceuticals Announces New Presentation Time at the Bank of America Global H..
GL
09/12Wedbush Raises Price Target on Apellis Pharmaceuticals to $67 From $55, Sees Increased ..
MT
More news
Analyst Recommendations on APELLIS PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 79,1 M - -
Net income 2022 -627 M - -
Net cash 2022 400 M - -
P/E ratio 2022 -11,5x
Yield 2022 -
Capitalization 7 504 M 7 504 M -
EV / Sales 2022 89,8x
EV / Sales 2023 27,4x
Nbr of Employees 476
Free-Float 84,5%
Chart APELLIS PHARMACEUTICALS, INC.
Duration : Period :
Apellis Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends APELLIS PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 18
Last Close Price 68,30 $
Average target price 77,82 $
Spread / Average Target 13,9%
EPS Revisions
Managers and Directors
Cedric Francois President, Chief Executive Officer & Director
Timothy Eugene Sullivan Chief Financial Officer & Treasurer
Lok Chung Chan Chairman
Pascal Deschatelets Chief Scientific Officer
Federico Grossi Chief Medical Officer
Sector and Competitors